Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George H Talbot

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 13, 2019
Widening the Overton Window-While Avoiding DefenestrationGeorge H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 6, 2010
Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumoniaGeorge H Talbot
Infection Control and Hospital Epidemiology|October 9, 2010
The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapesGeorge H Talbot
Current Opinion in Critical Care|August 30, 2018
Evolution and current status of United States Food and Drug Administration and European Medicines Agency regulatory guidance for studies of nosocomial pneumoniaGeorge H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2020
Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial PneumoniaGeorge H Talbot
Expert Review of Anti-Infective Therapy|February 7, 2008
What is in the pipeline for Gram-negative pathogens?George H Talbot
Annals of the New York Academy of Sciences|January 26, 2013
β-Lactam antimicrobials: what have you done for me lately?George H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2016
The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?George H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2008
Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?George H Talbot
Southern Medical Journal|October 1, 2003
Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillinRobert L Thompson, Bruce Lavin, George H Talbot
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 13, 2019
Widening the Overton Window-While Avoiding DefenestrationGeorge H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 6, 2010
Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumoniaGeorge H Talbot
Infection Control and Hospital Epidemiology|October 9, 2010
The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapesGeorge H Talbot
Current Opinion in Critical Care|August 30, 2018
Evolution and current status of United States Food and Drug Administration and European Medicines Agency regulatory guidance for studies of nosocomial pneumoniaGeorge H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 26, 2020
Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial PneumoniaGeorge H Talbot
Expert Review of Anti-Infective Therapy|February 7, 2008
What is in the pipeline for Gram-negative pathogens?George H Talbot
Annals of the New York Academy of Sciences|January 26, 2013
β-Lactam antimicrobials: what have you done for me lately?George H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2016
The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?George H Talbot
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2008
Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?George H Talbot
Southern Medical Journal|October 1, 2003
Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillinRobert L Thompson, Bruce Lavin, George H Talbot
Pageof 5